Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Smith antigen is a set of highly conserved core proteins—mainly designated as B (B1/B’/N), D (D1/D2/D3), E, F, and G—found within small nuclear ribonucleoproteins (snRNPs) essential for precursor mRNA (pre-mRNA) splicing in eukaryotic cells. Smith antigens comprise a “ring”-like protein structure that, together with small nuclear RNA, forms the backbone of the spliceosome—a complex responsible for the removal of introns and the creation of mature mRNA. Autoantibodies against Smith antigen (anti-Sm antibodies) are highly specific for SLE and serve as a key laboratory diagnostic marker, though they occur only in about 20–30% of SLE patients. The complex is not targeted by any current therapeutics; rather, its significance lies in its role as an autoantigen in autoimmune pathophysiology, especially in SLE and, less commonly, in other connective tissue diseases. Although Smith antigen is essential in RNA splicing, it has no direct role as a drug target or a receptor/enzyme in pharmacotherapy. Its clinical importance is almost exclusively in autoimmunity as the target of pathogenic autoantibodies, which guide diagnosis but not therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Smith antigen (snRNP core protein complex) (Sm antigen).